The role of angiogenesis in hematologic malignancies.
Several reports have highlighted the biologic relevance of angiogenesis in neoplastic disorders and its potential impact on prognosis. In this review, we focus on recent findings about angiogenesis and angiogenetic factors in hematologic malignancies. We summarize the body of evidence supporting the hypothesis that a common progenitor gives rise to cells of both the endothelial and the hematopoietic lineages, and the current knowledge about the involvement of normal stromal cells in bone marrow angiogenesis. We also discuss the methodological aspects of microvessel count as a measure of tumor angiogenesis. Finally, we describe the current therapeutic role of angiogenesis inhibitors and possible future strategies involving these agents.
Stasi
Roberto
R
Department of Medical Sciences, Regina Apostolorum Hospital, Via S. Francesco 50, 00041 Albano Laziale, Italy. roberto.stasi@libero.it
Amadori
Sergio
S
D001808:Blood Vessels / Q000166:cytology / Q000196:embryology / Q000254:growth & development; D001853:Bone Marrow / Q000098:blood supply / Q000473:pathology; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology*; D017154:Stromal Cells / Q000502:physiology
D006133:Growth Substances